Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 24, 2024 Filed Jan 26, 2024 21:33 UTC |
Walts Alan EdmundDirector
|
GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-007294 · tm244260-4_4seq1.xml · derivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · derivative.expiration_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:33 UTC |
Rubin Steven DDirector
|
GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-007293 · tm244260-3_4seq1.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · derivative.expiration_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:32 UTC |
Androski LindsayDirector
|
GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-007291 · tm244260-2_4seq1.xml · derivative · entry 1 Androski Lindsay · CIK 0001936604 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · derivative.expiration_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:32 UTC |
Aggarwal SumitDirector · PRESIDENT AND CEO
|
GrantRestricted Stock Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-007290 · tm244260-1_4seq1.xml · derivative · entry 1 Aggarwal Sumit · CIK 0001854362 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. F2 · derivative.expiration_date: The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:12 UTC |
Walts Alan EdmundDirector
|
GrantStock Options (Right to Buy) · Derivative | 2,859 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001104659-23-008604 · tm234943-4_4seq1.xml · derivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859 Underlying: Common Stock · 2,859 shares Expires 2033-01-30 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:09 UTC |
Rubin Steven DDirector
|
GrantStock Options (Right to Buy) · Derivative | 2,859 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001104659-23-008601 · tm234943-3_4seq1.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859 Underlying: Common Stock · 2,859 shares Expires 2033-01-30 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:08 UTC |
Kariv TomerDirector
|
GrantStock Options (Right to Buy) · Derivative | 2,859 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001104659-23-008599 · tm234943-2_4seq1.xml · derivative · entry 1 Kariv Tomer · CIK 0001568077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859 Underlying: Common Stock · 2,859 shares Expires 2033-01-30 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner. Read SEC document |
| January 30, 2023 Filed Jan 31, 2023 21:07 UTC |
Androski LindsayDirector
|
GrantStock Options (Right to Buy) · Derivative | 2,859 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001104659-23-008597 · tm234943-1_4seq1.xml · derivative · entry 1 Androski Lindsay · CIK 0001936604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859 Underlying: Common Stock · 2,859 shares Expires 2033-01-30 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on the first anniversary of January 30, 2023, and the remaining 50% of the underlying shares will vest in twelve (12) equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:04 UTC |
Aggarwal SumitDirector · PRESIDENT AND CEO
|
GrantStock Options (Right to Buy) · Derivative | 68,700 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001104659-23-007511 · tm234565-2_4seq1.xml · derivative · entry 1 Aggarwal Sumit · CIK 0001854362 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,700 Underlying: Common Stock · 68,700 shares Expires 2033-01-25 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| January 25, 2023 Filed Jan 27, 2023 21:02 UTC |
MODUR VIJAYHEAD OF R&D
|
GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001104659-23-007510 · tm234565-1_4seq1.xml · derivative · entry 1 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-25 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. Read SEC document |
| July 01, 2022 Filed Jul 7, 2022 01:50 UTC |
Androski LindsayDirector
|
GrantStock Options (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001104659-22-077837 · tm2220578-1_4seq1.xml · derivative · entry 1 Androski Lindsay · CIK 0001936604 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-07-01 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on July 1, 2023 and the remainder in twelve (12) equal monthly installments thereafter. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 12:29 UTC |
Walts Alan EdmundDirector
|
GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001104659-22-072191 · tm2218714-8_4seq1.xml · derivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 12:28 UTC |
Veinrib GadiDirector
|
GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001104659-22-072189 · tm2218714-7_4seq1.xml · derivative · entry 1 Veinrib Gadi · CIK 0001726015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 12:28 UTC |
Seehra JasbirDirector
|
GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001104659-22-072188 · tm2218714-6_4seq1.xml · derivative · entry 1 Seehra Jasbir · CIK 0001732369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 12:27 UTC |
Rubin Steven DDirector
|
GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001104659-22-072187 · tm2218714-5_4seq1.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 12:27 UTC |
PAREKH RAJESH BDirector
|
GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001104659-22-072185 · tm2218714-4_4seq1.xml · derivative · entry 1 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. F2 · balance_after: The Reporting Person will assign the economic interests of this grant to Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 12:26 UTC |
Nussbaum RanDirector
|
GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001104659-22-072179 · tm2218714-3_4seq1.xml · derivative · entry 1 Nussbaum Ran · CIK 0001609805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 12:24 UTC |
Kariv TomerDirector
|
GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001104659-22-072176 · tm2218714-2_4seq1.xml · derivative · entry 1 Kariv Tomer · CIK 0001568077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 12:23 UTC |
Avnur ZafriraDirector
|
GrantStock Options (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.26 | $0.00 |
DisclosureSEC source: 0001104659-22-072175 · tm2218714-1_4seq1.xml · derivative · entry 1 Avnur Zafrira · CIK 0001726049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal installments thereafter. Read SEC document |
| February 06, 2022 Filed May 8, 2026 20:53 UTC |
Aggarwal SumitDirector · President and CEO · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 42,790 | $0.00 Strike: $18.40 | $0.00 |
DisclosureSEC source: 0001193125-26-214890 · ownership.xml · derivative · entry 5 Aggarwal Sumit · CIK 0001854362 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,790 Underlying: Common Stock · 42,790 shares Expires 2032-02-06 F4 · shares: On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split. F3 · derivative.exercise_date: The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:16 UTC |
Walts Alan EdmundDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 37,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005694 · form4-12032021_021230.xml · derivative · entry 2 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,695 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:16 UTC |
Walts Alan EdmundDirector
|
Exercise / conversionCommon Stock | 37,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005694 · form4-12032021_021230.xml · nonDerivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:15 UTC |
Aggarwal SumitDirector · PRESIDENT AND CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 279,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005693 · form4-12032021_021217.xml · derivative · entry 3 Aggarwal Sumit · CIK 0001854362 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 279,158 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:15 UTC |
Aggarwal SumitDirector · PRESIDENT AND CEO
|
Tax withholdingCommon Stock | 81,933 | $0.72 | $58,991.76 |
DisclosureSEC source: 0001415889-21-005693 · form4-12032021_021217.xml · nonDerivative · entry 2 Aggarwal Sumit · CIK 0001854362 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,225 Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:15 UTC |
Aggarwal SumitDirector · PRESIDENT AND CEO
|
Exercise / conversionCommon Stock | 279,158 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005693 · form4-12032021_021217.xml · nonDerivative · entry 1 Aggarwal Sumit · CIK 0001854362 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:14 UTC |
MODUR VIJAYHEAD OF R&D
|
Exercise / conversionRestricted Stock Units · Derivative | 219,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005692 · form4-12032021_021220.xml · derivative · entry 3 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 219,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:14 UTC |
MODUR VIJAYHEAD OF R&D
|
Tax withholdingCommon Stock | 64,373 | $0.72 | $46,348.56 |
DisclosureSEC source: 0001415889-21-005692 · form4-12032021_021220.xml · nonDerivative · entry 2 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,953 Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:14 UTC |
MODUR VIJAYHEAD OF R&D
|
Exercise / conversionCommon Stock | 219,326 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-005692 · form4-12032021_021220.xml · nonDerivative · entry 1 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on April 1, 2021 have fully vested and settled for shares of the Issuer's common stock. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 16:06 UTC |
Geffken Daniel E.INTERIM CFO
|
PurchaseCommon Stock | 50,000 | $0.72 | $36,000.00 |
DisclosureSEC source: 0001415889-21-005600 · form4-12012021_081251.xml · nonDerivative · entry 1 Geffken Daniel E. · CIK 0001314756 · INTERIM CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: Price represents the average purchase price per share. Read SEC document |
| July 30, 2021 Filed Jul 31, 2021 00:32 UTC |
Belloff Neil S.COO, GENERAL COUNSEL &CORP SEC
|
Exercise / conversionRestricted Stock Units · Derivative | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003750 · form4-07302021_050735.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 1,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated with certain qualifying terminations of service or in connection with a corporate transaction. Read SEC document |
| July 30, 2021 Filed Jul 31, 2021 00:32 UTC |
Belloff Neil S.COO, GENERAL COUNSEL &CORP SEC
|
Tax withholdingCommon Stock | 459 | $1.32 | $605.88 |
DisclosureSEC source: 0001415889-21-003750 · form4-07302021_050735.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,699 Read SEC document |
| July 30, 2021 Filed Jul 31, 2021 00:32 UTC |
Belloff Neil S.COO, GENERAL COUNSEL &CORP SEC
|
Exercise / conversionCommon Stock | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003750 · form4-07302021_050735.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person onJanuary 30, 2019 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:10 UTC |
Belloff Neil S.COO, GENERAL COUNSEL &CORP SEC
|
Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002682 · form4-05262021_040501.xml · derivative · entry 3 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,750 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · price: The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. F4 · balance_after: The remaining restricted stock units will vest ratably each quarter through February 25, 2024, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:10 UTC |
Belloff Neil S.COO, GENERAL COUNSEL &CORP SEC
|
Tax withholdingCommon Stock | 1,835 | $1.39 | $2,550.65 |
DisclosureSEC source: 0001415889-21-002682 · form4-05262021_040501.xml · nonDerivative · entry 2 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,595 Read SEC document |
| May 25, 2021 Filed May 26, 2021 20:10 UTC |
Belloff Neil S.COO, GENERAL COUNSEL &CORP SEC
|
Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002682 · form4-05262021_040501.xml · nonDerivative · entry 1 Belloff Neil S. · CIK 0001741670 · COO, GENERAL COUNSEL &CORP SEC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on February 25, 2020 have partially vested and settled for shares of the Issuer's common stock. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:11 UTC |
Walts Alan EdmundDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,334 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001415889-21-002616 · form4-05202021_040547.xml · derivative · entry 1 Walts Alan Edmund · CIK 0001853544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 3,334 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:11 UTC |
PAREKH RAJESH BDirector
|
GrantStock Option (Right to Buy) · Derivative | 3,334 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001415889-21-002615 · form4-05202021_040542.xml · derivative · entry 1 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 3,334 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to Advent Life Sciences LLP. The Reporting Person is a general partner of Advent Life Sciences LLP. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC |
Avnur ZafriraDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001415889-21-002613 · form4-05202021_040532.xml · derivative · entry 1 Avnur Zafrira · CIK 0001726049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC |
Nussbaum RanDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001415889-21-002614 · form4-05202021_040537.xml · derivative · entry 1 Nussbaum Ran · CIK 0001609805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC |
Kariv TomerDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001415889-21-002612 · form4-05202021_040528.xml · derivative · entry 1 Kariv Tomer · CIK 0001568077 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. F2 · ownership.direct: The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC |
Veinrib GadiDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001415889-21-002611 · form4-05202021_040518.xml · derivative · entry 1 Veinrib Gadi · CIK 0001726015 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC |
Rubin Steven DDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001415889-21-002609 · form4-05202021_040501.xml · derivative · entry 1 Rubin Steven D · CIK 0001381874 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| May 19, 2021 Filed May 20, 2021 20:10 UTC |
Seehra JasbirDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001415889-21-002610 · form4-05202021_040512.xml · derivative · entry 1 Seehra Jasbir · CIK 0001732369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The stock option was issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: one half (1/2) of the shares underlying the option shall vest on May 19, 2022 (the "Cliff Vesting Date"), the remainder of the grant shall vest in twelve (12) equal installments on each successive monthly anniversary of the Cliff Vesting Date, subject to Reporting Person's continuous service as of each such date. Read SEC document |
| May 18, 2021 Filed May 18, 2021 21:48 UTC |
MODUR VIJAYHEAD OF R&D
|
GrantStock Options (Right to Buy) · Derivative | 496,204 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001415889-21-002555 · form4-05182021_020547.xml · derivative · entry 1 MODUR VIJAY · CIK 0001854082 · HEAD OF R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 496,204 Underlying: Common Stock · 496,204 shares Expires 2031-04-01 F1 · derivative.exercise_date: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan in accordance with the anti-dilution provisions of the Reporting Person's employment agreement in connection with a Qualifying Financing as defined therein. The stock options vest and become exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter, subject to Reporting Person's continued employment or other service with the Issuer on each applicable vesting date, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction. Read SEC document |
| May 18, 2021 Filed May 18, 2021 21:45 UTC |
Aggarwal SumitDirector · PRESIDENT AND CEO
|
GrantStock Options (Right to Buy) · Derivative | 992,409 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001415889-21-002554 · form4-05182021_050501.xml · derivative · entry 1 Aggarwal Sumit · CIK 0001854362 · Director · PRESIDENT AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 992,409 Underlying: Common Stock · 992,409 shares Expires 2031-04-01 F1 · derivative.exercise_date: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan in accordance with the anti-dilution provisions of the Reporting Person's employment agreement in connection with a Qualifying Financing as defined therein. The stock options vest and become exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter, subject to Reporting Person's continued employment or other service with the Issuer on each applicable vesting date, which vesting may be accelerated in connection with certain qualifying terminations of employment or in connection with a corporate transaction. Read SEC document |
| May 13, 2021 Filed May 17, 2021 11:03 UTC |
Pontifax (China) IV L.P.10% owner
Pontifax (Cayman) IV L.P.10% owner
Pontifax (Israel) IV, L.P.10% owner
Pontifax IV GP L.P.10% owner
|
PurchaseCommon Stock | 592,592 | $1.35 | $799,999.20 |
DisclosureSEC source: 0001104659-21-067336 · tm2116620d3_4.xml · nonDerivative · entry 4 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax IV GP L.P. · CIK 0001726353 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pontifax Investment Fund Disclosed balance after: 616,592 F1 · kind: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F1 · price: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F5 · ownership.nature: Represents shares of the Issuer held by Pontifax Late Stage Fund L.P.("Late Stage Fund"). Pontifax Late Stage GP Ltd. ("Late Stage GP"), the general partner of Late Stage Fund, has a Strategic Alliance Agreement with Pontifax IV. By virtue of this relationship, Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Late Stage Fund. Each of Management 4, Pontifax IV, Late Stage Fund and Late Stage GP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| May 13, 2021 Filed May 17, 2021 11:03 UTC |
Pontifax (China) IV L.P.10% owner
Pontifax (Cayman) IV L.P.10% owner
Pontifax (Israel) IV, L.P.10% owner
Pontifax IV GP L.P.10% owner
|
PurchaseCommon Stock | 1,422,222 | $1.35 | $1,919,999.70 |
DisclosureSEC source: 0001104659-21-067336 · tm2116620d3_4.xml · nonDerivative · entry 3 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax IV GP L.P. · CIK 0001726353 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pontifax Investment Fund Disclosed balance after: 1,989,551 F1 · kind: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F1 · price: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F4 · ownership.nature: Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| May 13, 2021 Filed May 17, 2021 11:03 UTC |
Pontifax (China) IV L.P.10% owner
Pontifax (Cayman) IV L.P.10% owner
Pontifax (Israel) IV, L.P.10% owner
Pontifax IV GP L.P.10% owner
|
PurchaseCommon Stock | 2,630,487 | $1.35 | $3,551,157.45 |
DisclosureSEC source: 0001104659-21-067336 · tm2116620d3_4.xml · nonDerivative · entry 2 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax IV GP L.P. · CIK 0001726353 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pontifax Investment Fund Disclosed balance after: 3,679,797 F1 · kind: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F1 · price: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F3 · ownership.nature: Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| May 13, 2021 Filed May 17, 2021 11:03 UTC |
Pontifax (China) IV L.P.10% owner
Pontifax (Cayman) IV L.P.10% owner
Pontifax (Israel) IV, L.P.10% owner
Pontifax IV GP L.P.10% owner
|
PurchaseCommon Stock | 1,280,624 | $1.35 | $1,728,842.40 |
DisclosureSEC source: 0001104659-21-067336 · tm2116620d3_4.xml · nonDerivative · entry 1 Pontifax Management 4 G.P. (2015) Ltd. · CIK 0001726334 · 10% owner Pontifax (China) IV L.P. · CIK 0001726030 · 10% owner Pontifax (Cayman) IV L.P. · CIK 0001726029 · 10% owner Pontifax (Israel) IV, L.P. · CIK 0001726039 · 10% owner Pontifax IV GP L.P. · CIK 0001726353 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pontifax Investment Fund Disclosed balance after: 1,791,470 F1 · kind: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F1 · price: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F2 · ownership.nature: Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise. Read SEC document |
| May 13, 2021 Filed May 17, 2021 13:22 UTC |
PAREKH RAJESH BDirector
|
PurchaseCommon Stock | 2,381,890 | $1.35 | $3,215,551.50 |
DisclosureSEC source: 0001104659-21-067516 · tm2116620d4_4.xml · nonDerivative · entry 2 PAREKH RAJESH B · CIK 0001429930 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,827,129 F1 · kind: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F1 · price: Reflects the purchase of shares in the offering of Common Stock of Eloxx Pharmaceuticals, Inc. that is expected to close on May 18, 2021. F3 · ownership.nature: Held directly by Advent Life Sciences Fund II LP. Advent Life Sciences LLP is the manager of Advent Life Sciences Fund II LP and the Reporting Person is a general partner of Advent Life Sciences LLP. The Reporting Person disclaims beneficial ownership of the reported shares, except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.